找回密码
 新注册用户
搜索
楼主: vmzy

[独立平台] [生命科学类] Folding@Home

[复制链接]
 楼主| 发表于 2014-10-3 16:34:48 | 显示全部楼层
New FAH Assignment Server Deployed
October 1, 2014 by Mark Piercy ·
After over a year of internal development, we have deployed the new Folding@home Assignment Server (AS). The AS plays a central role in FAH. AS logic decides the “what” and “where” of Work Unit/Project assignment, i.e. what types of projects should be placed on which Work Servers (WS), among other things.

The new AS has several major benefits. It has the ability to more cleanly handle involvement of multiple Pande Group/Pande Group-associated Work Server maintainers. Assignments are now based on projects rather than Work Server type/availability. So now we have better control of pushing out our projects. We also have much better AS to WS connections thus avoiding the “no work” messages or other errors that resulted from slower AS/WS communication. The new WS now has a suite of analytics to help us better analyze how FAH assignments are working and improve issues much earlier, ideally before they become more serious.
大意:
新的AS服务器代码部署完毕
历经一年的内测,新的AS代码已经部署到服务器上了。老AS主要负责分配WS服务器。
新的AS代码主要分配子项目(不仅仅是WS服务器),而且改进了AS和WS的通信机制,当AS/WS连接缓慢的时候,不再报‘没有任务’的错误。而且现在新WS服务器有了一套更加完善的分析功能。能够更好的监控项目状态,也能更早的发现问题。

评分

参与人数 1基本分 +30 维基拼图 +20 收起 理由
xx318088 + 30 + 20

查看全部评分

回复

使用道具 举报

 楼主| 发表于 2014-10-3 17:05:34 | 显示全部楼层
Working with Andreessen Horowitz
October 2, 2014 by Vijay Pande ·
Starting this week, I am adding an additional role to my work at Stanford (currently Director of Biophysics; Professor of Chemistry, and by courtesy, Computer Science, and Structural Biology; and Director of Folding@home) by doing consulting for Andreessen Horowitz (aka “a16z”), a venture capital firm with the goal of supporting companies with an emphasis on software making the difference.  Just as the web browser has changed the world, they are looking to support new ideas with a similar transformative character.  My role will be to be a conduit between academia and venture capital, to help good ideas at Universities to get the funding they need to create new products to help the world.  I’d like to stress that the Folding@home team is continuing full steam and that this new role has the hope for improved funding for activities at Stanford and for academic researchers in general.
大意:
我(Vijay Pande)已有的职责包括:生物物理学系主任;化学系教授;计算机科学和结构生物学名誉教授;FAH负责人。现在我又多了个新角色,Andreessen Horowitz风投公司(VC)顾问。我的职责主要是在学校和风投之间牵线搭桥,为大学里的好项目寻找资金支持。


Upgraded Maxwell support for Core17
October 2, 2014 by Vijay Pande ·
With the newer NVIDIA drivers, it looks like Core17 works well on Maxwell.  We’ve released Core17 to Maxwell on adv (“Advanced Methods” setting).  If you’re having problems, you can set from adv back to the regular fah setting, allowing donors to opt out if they’re having problems.  The latest drivers are recommended.
大意:
最新版的Maxwell驱动支持Core17了,FAH加上adv标签后就可以接新任务了。

评分

参与人数 1基本分 +30 维基拼图 +20 收起 理由
xx318088 + 30 + 20

查看全部评分

回复

使用道具 举报

 楼主| 发表于 2014-10-9 10:15:33 | 显示全部楼层
Combining simulation and experiments to solve molecular structures
October 8, 2014 by Vincent Voelz ·
The Voelz lab has been making progress on combining simulation and experiments to solve molecular structures.

Most molecules do not have a single rigid structure in solvent. Instead, they exist in a range of different conformations. Stable proteins exist mostly in the folded conformation, but there is always a small fraction of population that is unfolded. Other molecules may have a very heterogeneous set of conformations, which can make determining their structure in solvent difficult. NMR experiments, for example, can be used for this, but structural information often gets “washed out” due to motional averaging.

Our new method, called BICePs (Bayesian inference of conformational populations) is a robust method to infer the populations of conformational states, using a combination of high-resolution computer modeling and information from experiments. We think BICePs will be very useful for determining the extent to which proteins and other molecules are well-structured in solution. In the future we plan to use it as a tool for designing well-structured mimics of proteins, called peptidomimetics. Our paper describing the new BICePs algorithm has been published in the latest issue of the Journal of Computational Chemistry.
大意:
Voelz实验室在将模拟和实验结合起来解析分子结构技术方面取得进展
大多数分子在溶剂中都存在不止一个刚性结构。稳定的蛋白质大多处于折叠态,但也很小一部分处于非折叠态。一部分分子还拥有许多不同类型的构象。这就决定了确定分子在溶剂中的结构是相当困难的。虽然核磁共振实验可以用来获得分子结构,但是由于动态平衡机制,这些静态结构大多是假的。
我们发明的新方法叫BICePs(构象族群贝叶斯推导法),是一种利用高分辨率计算机模拟结构数据和试验数据推导出构象族群的方法。新方法的算法我们发表在了最新一期的《计算化学》杂志上。

评分

参与人数 1基本分 +30 维基拼图 +30 收起 理由
xx318088 + 30 + 30

查看全部评分

回复

使用道具 举报

 楼主| 发表于 2014-10-11 23:00:55 | 显示全部楼层
A new project to study early folding events in apomyoglobin
October 10, 2014 by Vincent Voelz ·
In a new NSF-funded collaboration, the Voelz Lab is working with the Roder Lab at Fox Chase Cancer Center to study early folding events in apomyoglobin.

Apomyoglobin (myoglobin without the heme group) is an extremely well-studied protein. In fact, mygolobin was the first protein to have its structure solved by x-ray crystallography (John Kendrew, 1958). At low pH, apomyoglobin assumes a “molten globule” state that is compact and only partially structured. Seminal experiments by Jennings and Wright (1993) showed that when apomyoglobin folds at normal pH, it goes through an early intermediate that closely corresponds to the low-pH molten globule state.

Now, more recent experiments from the Roder lab have revealed even more details of early folding events in myoglobin (Xu et al. 2012). Using Trp fluorescence spectroscopy in a continuous-flow fast mixer, the Roder lab have resolved the formation of up to four different conformational states, on timescales ranging from microseconds to milliseconds.

The Voelz Lab is working toward using molecular simulation to characterize these conformational states in atomic detail. Both the size of the protein (153 residues) and the timescale of early folding (~200 µs) make this a challenging problem to tackle, but we hope that simulations on Folding@home (coming soon!) combined with Markov State Model approaches will enable us to construct a highly detailed model of the early folding reaction, and new level of quantitative connection between simulations and experiments. In the years to come, this work will lead to new ways to combine computation and experiment to understand and fight human diseases.
大意:
开始有关脱辅基肌红蛋白的新项目
脱辅基肌红蛋白的结构已经被仔细研究过(它是第一个通过x射线晶体成像术弄清结构的蛋白质)。在低PH值环境下,脱辅基肌红蛋白就像融化的小球一样。在后续的试验中发现在正常的PH值下,脱辅基肌红蛋白会开始折叠,变成另外一种类似的中间态。近期通过Trp荧光光谱标记技术的研究,又发现4种不同的构象态。
Voelz实验室试图通过分子模拟技术,在原子级别研究这些构象态。由于这个分子比较大(153个残基),折叠时长较长(约200微秒)。我们希望利用FAH(项目很快会开始)和马尔可夫模型法来仔细研究它,并观察模拟结果和实验结果的差异。长远来看,这有利于寻找将模拟计算和实验结合的新研究方法,来研究和治疗人类疾病。

评分

参与人数 1基本分 +30 维基拼图 +40 收起 理由
xx318088 + 30 + 40

查看全部评分

回复

使用道具 举报

 楼主| 发表于 2014-10-14 11:20:05 | 显示全部楼层
Investigating conformations accessible by Abl kinase- drug target for chronic myelogenous leukemia
October 13, 2014 by Mark Piercy ·
Guest post by Sonya Hanson, postdoc in the Chodera lab.
(Project 10472)

We’re working our way through the kinase family here at the Chodera lab. You may have seen Danny’s post about EGFR earlier this year, and now we’ve started simulations of Abl kinase. Abl kinase has a special place in the history of cancer therapeutics, ‘dispelling the long-held myth that it was not feasible to develop selective inhibitors of key cell-signaling molecules as safe and effective medicines.’ Novartis’ development of the drug imatinib (or Gleevec commercially) to treat chronic myelogenous leukemia (CML) specifically targets a mutant Abl kinase that results from a chromosomal abnormality called ‘the Philadelphia chromosome’. There is even a book out recently that chronicles the development of Gleevec (The Philadelphia Chromosome).

While the success of imatinib was remarkable, many patients develop resistance to it and regress. A more recent drug targeting Abl kinase, ponatinib of Ariad Pharmaceuticals (Iclusig commercially), has been developed that overcomes some of these resistance mutations. However, now even ponatinib has been found to be susceptible to resistance mutants. With these simulations of Abl kinase, we are hoping to begin to understand a structural basis for the development of resistance mutants so we can develop drugs that anticipate and overcome them before the patient even has to experience regression. But to do this we will need many long timescale trajectories of Abl and later its mutants to achieve this deeper understanding of the development of resistance in CML. Additionally, this knowledge could inform models of resistance development in other cancers that result from kinase mutations or kinase up-regulation.


大意:
研究慢性粒细胞白血病(血癌)标靶——ABL激酶的构象
ABL激酶在抗癌史上有着举足轻重的地位。诺瓦提斯开发了伊马替尼(商业名称是格列卫)用于治疗血癌,它的主要标靶是一种变异的ABL激酶(可以导致染色体异常)。最近新出了一本有关格列卫编年史的新书,有兴趣的可以去看下。
尽管伊马替尼很出名,但是仍有很多病人对它产生了抗药性和复发。最新的ABL激酶药物是Ariad制药公司的ponatinib,虽然它的确能治愈某些抗药性变异,但是对个别抗药性变异依然束手无策。
我们希望通过对ABL激酶的模拟研究,研发新的不易产生抗药性,并且不易产生复发的药物。为此我们需要进行长时间量级的模拟计算。此外,此次可以对其他癌症激酶的抗药性变异研究打下基础,远期效益可观。

评分

参与人数 1基本分 +30 维基拼图 +50 收起 理由
xx318088 + 30 + 50

查看全部评分

回复

使用道具 举报

 楼主| 发表于 2014-10-21 09:44:49 | 显示全部楼层
New projects to help design selective inhibitors of protein methyltransferases
October 20, 2014 by john Chodera ·
The Chodera lab has teamed up with Luo lab at MSKCC to study another important class of cancer targets: protein methyltransferases.

These are protein-modifying enzymes that catalyze the transfer of methyl groups to lysine or arginine residues as part of complex regulatory programs. While a number of cancers have alterations in protein methyltransferases, making them appealing targets for new anticancer therapeutics, it is not yet possible to fully understand their role in disease because of the current limited repertoire of compounds available to selectively inhibit these enzymes.

Spurred by recent encouraging results from the Luo lab in developing sinefungin scaffolds to selectively target key methyltransferases, we are working with them to better understand the origin of selectivity of these compounds, and to help them design new compounds that will allow researchers to better understand the roles these enzymes play in cancer and, eventually, develop potent new anticancer therapeutics.

Projects 10474, 10475, and 10476 study key protein methyltransferases NSD1, NSD2, and SETD2.


protein methyltransferase NSD1 (PDB ID 4h12)
大意:
新项目:设计甲基转移酶靶向抑制剂
甲基转移酶可以把甲基团转移到赖氨酸或精氨酸残基上,使蛋白质发生变性。这是一种潜在的癌症治疗方法。
子项目10474, 10475, 10476分别研究NSD1、NSD2、SETD2三种关键甲基转移酶。

评分

参与人数 1基本分 +30 维基拼图 +10 收起 理由
xx318088 + 30 + 10

查看全部评分

回复

使用道具 举报

 楼主| 发表于 2014-10-25 23:09:12 | 显示全部楼层
Project 10470 and T4 Lysozyme
October 24, 2014 by Mark Piercy ·
(Guest post by Kyle Beauchamp from the Chodera lab.)

In the Chodera lab, we’d like to understand how drugs bind to proteins, particularly for challenging diseases such as cancer or Alzheimer’s. To get to this point, however, will require a lot of hard work on simple systems—systems where we already “know the answer”.

T4 Lysozyme has been a key model system for understanding protein stability (Matthews, 2010). A version of T4 Lysozyme—with mutation L99A—binds a number of greasy molecules like benzene (see picture, PDBID 3DMX). Our hope is that a better understanding of how T4 Lysozyme L99A binds various molecules could lead us to better models for drug binding. (Mobley, 2007).

Project 10470 simulates T4 Lysozyme mutant L99A. These simulations will be used to improve models for ligand binding.

大意:
T4溶菌酶,是一个研究蛋白质稳定性的理想模型。带有L99A变异的T4溶菌酶,可以绑定很多‘滑腻的’分子(比如苯)。我们的目标是通过10470项目更好的研究带有L99A变异的T4溶菌酶的绑定机制。这样我们将来就可以研究出配体绑定性能更好的药物(靶向性更高、更有效)

评分

参与人数 1基本分 +30 维基拼图 +16 收起 理由
xx318088 + 30 + 16

查看全部评分

回复

使用道具 举报

 楼主| 发表于 2014-10-28 09:51:26 | 显示全部楼层
Bowman lab update on vision
October 27, 2014 by Greg Bowman ·
About four months ago, we started a new set of projects to understand the dynamics of some of the key proteins involved in vision.  Now, we have about 600 microseconds of simulation and have begun some preliminary analysis of the data.  Excitingly, it appears we may already have captured the conformational change we were targeting.  More data will be needed to improve the statistical significance of our results, but we are increasingly confident that we’ll be able to begin understanding some of the conformational changes required for vision and, eventually , how mutations lead to various blinding diseases.
大意:
几个月前我们开始了视色素的研究,如今我们已经得到了大概600毫秒的模拟数据,而且已经开始了初步的数据分析工作。振奋人心的是,我们貌似一击即中,已经找到了试图寻找的构象变换。为了提高结果的统计学精度,我们还要进行更多的模拟数据。不过我们相信,依靠这些数据,我们能揭开某些视色素变异导致致盲的机理。

评分

参与人数 1基本分 +30 维基拼图 +19 收起 理由
xx318088 + 30 + 19

查看全部评分

回复

使用道具 举报

 楼主| 发表于 2014-11-6 14:31:46 | 显示全部楼层
Bryostatin and Projects 9000-9015
November 5, 2014 by Mark Piercy ·
Steven Ryckbosch, a graduate student in the Pande Group recently presented his work on Bryostatin. Folding@home projects 9000-9015 are running simulations to help answer the questions he has about it’s structure and function.

Bryostatin is a naturally occurring marine molecule that shows promising and unique activity against several diseases (most notably, cancer, HIV/AIDS, HIV latency, and Alzheimer’s). Its main target, protein kinase C (PKC), is a signaling protein central to many cellular functions. In its active form, PKC binds its ligand and is associated with the cell membrane, but we currently lack structural information about this complex in its membrane microenvironment.

The simulations performed on FAH will help to provide a structure to the PKC-ligand-membrane complex. This is complicated by the fact that while other compounds such as the phorbol esters also bind to PKC, they exhibit extremely different effects in cells and organisms. The structure and dynamics of this complex would allow us to understand bryostatin and other ligands’ binding mode and thus how to modify and tune it’s structure to improve function or even create new functions as needed for new therapies in the clinic.

Some questions Steven and the group are trying to answer:

How can we use simulation to find protein-membrane structures?
How can ligands modulate protein-membrane interaction?
How are membranes affecting bryostatin function?
How can this inform our design of new bryostatin analogues?

Below is a molecular simulation model of bryostatin bound to PKC’s active site.

大意:
9000-9015项目研究的是苔藓抑素,这是一种自然产生的水生生物分子,它对很多疾病(癌症、艾滋、阿兹海默)都有效用。它的主要靶点是C型激酶(PKC)。PKC是一种重要的信号蛋白,它通过把配体结合在细胞膜上发生效用。但是目前我们对PKC配体的膜融合结构缺乏了解。更复杂的是如果其它分子(比如佛波脂)也与PKC结合,它会在细胞和组织中表现出不同的效用。通过FAH我们可以对PKC有更多的了解,将来我们可以加强它的功效或者研发新的功效用于临床治疗。
通过FAH的模拟计算我们希望解决如下问题:
利用模拟我们能发现多少蛋白膜结构的秘密?
配体与蛋白膜的交互关系?
不同的细胞膜是否会影响苔藓抑素的功能?
据此我们能否设计出新的苔藓抑素同源体?

评分

参与人数 1基本分 +30 维基拼图 +50 收起 理由
xx318088 + 30 + 50

查看全部评分

回复

使用道具 举报

 楼主| 发表于 2014-11-8 10:48:24 | 显示全部楼层
Ab initio nanoreactor discovers new reaction pathways
November 7, 2014 by Mark Piercy ·
Some very exciting research by Pande Group members Lee-Ping Wang and Robert McGibbon in collaboration with the Martinez Lab was recently published in Nature Chemistry. They report the development and application of the ab initio nanoreactor—a highly accelerated first-principles molecular dynamics simulation of chemical reactions that discovers new molecules and mechanisms.

Using the nanoreactor, they showed new pathways for the amino acid glycine’s synthesis from primitive compounds proposed to exist on the early Earth, which provide new insight into the classic Urey–Miller experiment. These results highlight the emergence of theoretical and computational chemistry as a tool for discovery.

The nanoreactor simulations were made possible by GPUs and the TeraChem quantum chemistry software; these technologies accelerate the calculation over conventional CPU codes by 10-100x.

Below is the nanoreactor simulation of the classic Urey–Miller experiment.
http://www.youtube.com/embed/WHQn03ZiqKY?rel=0
大意:
使用自主研发的ab initio nanoreactor软件,Pande Group 小组成员 Lee-Ping Wang 和 Robert McGibbon发现了新的甘氨酸(可能在早期地球出现的原始分子)合成通路。

评分

参与人数 1基本分 +30 维基拼图 +10 收起 理由
xx318088 + 30 + 10

查看全部评分

回复

使用道具 举报

 楼主| 发表于 2014-11-15 22:38:46 | 显示全部楼层
A discussion of recent FAH work on ab initio nanoreactor
November 14, 2014 by Jingcheng Wu ·
What’s an ab initio nanoreactor for?

In an ab initio nanoreactor, molecules are allowed to react freely with each other over the course of the molecular dynamics simulation, and then we observe what products come out of it and how the products were formed. Besides obeying the fundamental laws of physics, no additional assumptions were imposed to the system, hence ab initio.

The number of reactant molecules used to seed the simulations was small (50-100 molecules) compared to the number of molecules typically used in experimental methods, but is nonetheless very large from the standpoint of quantum chemistry calculations. To make the reactions occur more rapidly, we periodically push the molecules to the center of the ab initio nanoreactor with a virtual piston. What this does is to make the molecules bump into one another more frequently, and also provide the energy required for certain reactions to take place.

The significance of ab initio nanoreator

Traditionally, experimental methods are heavily relied on to discover new molecules and reaction pathways, and computational methods mainly played a supportive role to complement experimental methods. The results of this study prove that computational methods can also play the leading role in discovery, and can help guide experimental methods by posing new hypotheses and suggesting which experiments to do. It’s especially useful for detecting complex chemical reactions where several things happen at the same step during the reaction process that’s hard to detect via experiments.

The potential applications of ab initio nanoreactors are broad. Because of the ab initio approach coupled with some refinement methods and automatic analysis, we can achieve the goal of discovering new molecules, new reaction pathways and mechanisms in many different settings and environments. For instance, it could contribute to out future understanding of the origin of life, birth of stars, means to increase the rate of chemical reactions, earth’s atmosphere, etc.

Results of the study

We carried out two ab initio nanoreactor simulations. The first simulation started with purely acetylene molecules, and we call it acetylene nanoreactor. The second simulation started with a mixture of chemicals postulated to exist in the early earth atmosphere. The second simulation is the computational version of a famous experiment conducted in 1952 (Urey-Miller experiment) that showed complex building blocks of life could form from simple inorganic molecules (1). We call the second simulation Urey-Miller nanoreactor.

For the acetylene nanoreactor, nearly 100 distinct products were formed after ~500 picoseconds simulation time. Many of these product molecules are large (up to over 70 atoms) due to the tendency of acetylene molecules to form long chains and 3D networks. These products are also diverse, for example some have rings some don’t; some are linear some are branched. After comparing our results with those of previous experiments, we found that the acetylene nanoreactor produced not only similar products, but also new products (2, 3).

For the Urey-Miller nanoreactor, the products were relatively small (up to 16 atoms). Among the discovered products, we have amino acids (which are what proteins consist of), urea (participating in metabolism, and the first byproduct of life to be synthesized in the lab) and a bunch of other molecules, all of which have also been detected in meteorites that may have delivered organic molecules to the early earth (4). Many of these molecules are also found in interstellar clouds (5). In addition to the high diversity of products, the Urey-Miller nanoreactor also identified a complex network of reactions (more than 700 distinct reactions). A significant fraction of these reactions are viable in the common environment we live in. Moreover, we found out that water and ammonia allow reactions to proceed faster with less energy for many of these reactions. Last but not least, hydrogen was found rarely involved in the synthesis of a naturally occurring amino acid, glycine, which supports previous proposals that molecules that tend to lose electrons (including hydrogen) don’t participate in biomolecule formations (4).

Method of analysis

To derive insight from a complex network of reactions, we focus on a particular molecule in the network and investigate the reactions it’s involved in, either it’s the product or the reactant. In this way, it allows us to trace the synthetic pathways that lead from the starting molecules. There could be several different pathways to get from the starting material to our molecule of interest. Some intermediate molecules are more common than the others among these distinct pathways.

References

(1) Miller, S. L. & Urey, H.C. Organic Compound Synthesis on the Primitive Earth. Science 130, 245-251 (1959). Doi: 10.1126/science.130.3370.245

(2) Trout, C.C. & Badding, J.V. Solid State Polymerization of Acetylene at High Pressure and Low Temperature. J. Phys. Chem. A 104, 8142-8145 (2000).

(3) Sakashita, M., Yamawaki H. & Aoki, K. FT-IR Study of the Solid State Polymerization of Acetylene Under Pressure. J. Phys. Chem. 100, 9943-9947 (1996).

(4) Danger, G., Plasson, R. & Pascal R. Pathways For the Formation and Evolution of Peptides in Prebiotic Environments. Chem. Soc. Rev. 41, 5416-5429 (2012).

(5) Menten, K. M. & Wyrowski, F. in Sterstellar Molecules: Their Laboratory and Interstellar Habitat (eds Yamada, K. M. T. & Winnewisser, G.) 27-42 (Springer Tracts in Modern Physics 241, Springer, 2011).

Everything else described here is from Wang, L. P., Titov, A. McGibbon, R., Liu, F., Pande, V. S. & Martinez, T. J. Discovering Chemistry With An ab initio Nanoreactor. Nature Chemistry. 2014. Doi: 10.1038/nchem.2099. The article can also be read about on Nov 10th issue of C&E News: http://cen.acs.org/articles/92/i ... ction-Products.html
大意:
ab initio nanoreactor的介绍
什么是ab initio nanoreactor?
在an ab initio nanoreactor中,我们模拟一堆分子的交互作用。一般只模拟50-100个分子。在试验中这个分子数量很常见,但是对量子化学计算而言,这是非常多的。同时为了加快模拟速度我们会把分子尽量挤到一起。

an ab initio nanoreactor的重要性
一般来说,实验法主要用来发现新的分子和反应通路,而计算法只起到辅助作用。但是通过最近的研究,我们发现计算也可以主导实验法,先用计算模拟假设理论结果,再来实验验证。an ab initio nanoreactor的应用非常广泛,包括发现新分子,新反应通路,生命起源,星系诞生,催化技术,地球大气等等。

研究结果
我们进行了两个模拟,先是纯乙炔分子,再是早期地球大气的混合分子(即著名的尤里-米勒实验
第一个实验中,我们进行了5百皮秒的模拟,发现生成了上百种分子,不仅包括已知的分子,还发现了很多新分子。
而尤里-米勒模拟中,生成很多小分子,包括氨基酸(蛋白质的基本成分),尿素(参与新陈代谢,也是实验室合成的第一种生命物质)还有很多其他分子。他们都普遍存在于陨星或星云中。同时我们发现了一系列复杂的连锁反应(超过7白种),大部分都存在于我们生活的环境中。我们还发现了水和氨可以起到催化作用。此外我们还发现在甘氨酸的合成过程中,氢分子基本上不参与反应。


译注:这货太强大,绝逼大突破。今后拿诺贝尔的概率相当大啊!

评分

参与人数 1基本分 +30 维基拼图 +50 收起 理由
xx318088 + 30 + 50

查看全部评分

回复

使用道具 举报

 楼主| 发表于 2014-11-21 17:46:57 | 显示全部楼层
Breast Cancer and Her2 Kinase: Projects 9104-9114
November 20, 2014 by Mark Piercy ·
We are continuing to make a big push into studying cancer. Next up, is work relevant for breast cancer. Specifically, we have started to study the Her2 Kinase, a part of the EGFR family of Tyrosine kinases, responsible for initiating a host of biochemical pathways. These kinases are critical for regulating cell division and thus mutations within the EGFR family have been linked to various types of cancers, including breast and pancreatic cancer.

The aim of projects 9104 to 9114 is to understand the effect of certain mutations in the kinase domain of Her2. We are also hoping to find new druggable states within the system for creating the next generation of targeted cancer therapeutics, as well as to study the effect of mutations, which will give us insight into mutations present in breast cancer tumors.

her2

Model of ATP bound to Her2 Kinase
大意:
项目9104-9114研究乳腺癌和Her2激酶的关系
Her2激酶隶属于EGFR家族是一种酪氨酸激酶,主要是控制细胞分裂,很多癌症与EGFR家族有关,比如乳腺癌、胰腺癌。
项目9104-9114主要研究Her2激酶,试图需找可用于开发药物的靶点,以便开发下一代癌症靶向疗法。同时也对乳腺癌肿瘤中的Her2激酶变异进行深入研究。
回复

使用道具 举报

 楼主| 发表于 2014-11-26 11:08:01 | 显示全部楼层
Exploring how mutations affect folding using Markov State Models
November 25, 2014 by Vincent Voelz ·
A powerful method to understand folding and conformational change in proteins has been the Markov State Model (MSM) approach, in which protein dynamics can be described as a network of conformational states connected by forward and backward transition rates. Folding@home has proved to be an extremely valuable tool for constructing MSMs, because large-scale simulations are needed to sample the relevant states (numbering in the tens of thousands or more) and estimate the rates (by observing how many transitions are made over the course of many trajectories).

The Voelz lab has been working on using MSMs to understand how small changes to a protein, like a single-point mutation or chemical modification, perturb the transition rates. Not surprisingly, perturbations affect some states more than others. It turns out that a particular statistical metric, called the surprisal, can be used to identify the states most affected by perturbations. Using this metric, we can reveal the mechanisms by which perturbations affect dynamics; in the future, this may help us better understand the role of disease-causing mutations. We can also use the surprisal metric to choose states on which to focus more simulations, to help us efficiently interrogate the consequences of different chemical modifications. In this way, we hope to be able to use molecular simulation to help design drugs that mimic stable protein folds. The work is described in a new article published in the Journal of Chemical Theory and Computation (http://dx.doi.org/10.1021/ct500827g).

Surprisal metrics help reveal the conformational states of an alpha-helix most perturbed by salt-bridge mutations
大意:
使用马尔可夫模型研究变异是如何影响折叠的
FAH可以利用马尔可夫模型模拟分子的不同构型,以及它们的变换速率。Voelz实验室,试图搞清楚,一个点的变异或者化学修改,会对变换速率造成什么影响。他们发现某些特定的构型(把他们命名为surprisal)很容易受到影响。将来我们可以把模拟的重点放在这些敏感的构型上,以加快药物研发速度。
回复

使用道具 举报

 楼主| 发表于 2014-12-28 15:01:58 | 显示全部楼层
Fighting cancer on Folding@home: FDA approved kinase inhibitors
December 26, 2014 by Sonya Hanson ·
You may have noticed a trend in the type of proteins being simulated on Folding@home recently. A number of Folding@home labs are collaborating in an attempt to understand the role of protein conformational heterogeneity (the diversity of structures a protein can readily adopt) in the binding of small molecule drugs that target kinases, proteins that are mutated in a variety of cancers. A number of targeted kinase inhibitors have already been approved by the FDA, and have been shown to significantly improve the lives of patients with breast cancer, as with HER2 inhibitors, chronic myelogenous leukemia, as with Abl inhibitors, and other cancers. We’ve put together an informational poster with the FDA approved small molecule kinase inhibitors. Almost half of these molecules target kinases running on Folding@home: Lapatinib and Afatinib target HER2 (projects 9104-9114); Imatinib, Dasatinib, Ponatinib, Nilotinib, and Bosutinib target Abl (project 10472); Gefitinib, Erlotinib, and Afatinib target EGFR (project 10473); and Dasatinib and Bosutinib also target Src kinase (project 10471). Stay tuned for more blog posts on our progress in this area.

kinase_inhibitor_dorm_room_poster

PDF available here: kinase_inhibitor_dorm_room_poster
大意:
FDA核准了一批激酶抑制剂,可用于治疗乳腺癌(9104-9114项目)、白血病(10472项目)、其他癌症(10473、10471)。
回复

使用道具 举报

 楼主| 发表于 2015-1-2 12:40:07 | 显示全部楼层
Restriction of some GPU projects to pre-maxwell GPUs
January 1, 2015 by Vijay Pande ·
Given some known driver issues with recent NVIDIA maxwell chips and Core18 (https://www.reddit.com/r/folding ... ed_maxwell_support/), we are temporarily restricting our core18 projects (e.g. 1047*) to use pre-maxwell GPUs. We’ll be making the changes Friday morning. Hopefully this restriction will be a temporary fix, with full maxwell support for FAH in NVIDIA drivers (fixing an OpenCL bug) in the (hopefully near) future.

You can follow this thread in the FCF:

https://foldingforum.org/viewtopic.php?f=74&t=27208
大意:
由于NVIDIA maxwell 的驱动与Core18有兼容性问题。决定于周五起,暂停往maxwell架构显卡发送Core18任务。待NVIDIA官方解决驱动问题后,恢复任务发放。
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 新注册用户

本版积分规则

论坛官方淘宝店开业啦~
欢迎大家多多支持基金会~

Archiver|手机版|小黑屋|中国分布式计算总站 ( 沪ICP备05042587号 )

GMT+8, 2024-4-20 03:43

Powered by Discuz! X3.5

© 2001-2024 Discuz! Team.

快速回复 返回顶部 返回列表